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The hepatitis B surface antigen (HBsAg) is produced by transla-
tion of mRNAs of transcriptionally active HBV cccDNA as well
as from integrated HBV sequences coding for the surface protein.
The clinical utility of HBsAg quantiﬁcation in monitoring the nat-
ural history of chronic hepatitis B (CHB) and in evaluation of
response to anti-viral treatment continues to capture the atten-
tion of the hepatology community for more than a decade [1–
6]. Although at least three standardized immuno-assays for quan-
tiﬁcation of HBsAg are now commercially available [7], its utiliza-
tion is frequently restricted to academic institutions and research
centers. Both HBV-DNA and HBsAg levels ﬂuctuate during the
various phases of chronic HBV infection, being high in the initial
immune-tolerant phase and usually fading over age except dur-
ing periods of HBV reactivation. Serum levels of circulating HBsAg
are controlled, at least in part, by the amount of intra-hepatic
cccHBV-DNA, as well as by speciﬁc immune response(s) against
the envelope proteins. In general, both HBV-DNA and HBsAg lev-
els are higher in treatment-naive HBeAg positive as compared to
anti-HBe positive CHB patients. In recent years various studies
evaluated the utility of HBsAg quantiﬁcation in assessment of
anti-viral response to interferon as well as to nucleot(s)ide ana-
logues. Indeed, it has repeatedly been shown that decreasing
HBsAg levels can predict clearance of HBsAg and anti-HBs sero-
conversion in the relatively small number of patients who resolve
the persistent viral infection. Overall, there is already a consensus
that in addition to measurements of viral load through HBV-DNA
monitoring, HBsAg quantiﬁcation may be helpful in the predic-
tion of response or non-response to anti-viral treatment for both
HBeAg positive and HBeAg negative CHB patients (reviewed in
[5]). However, it soon became clear that there seem to be signif-
icant geographic variations in the kinetic as well as the positive
and negative predictive values of threshold HBsAg levels, which
forecast response or non-response to anti-viral treatment espe-
cially in HBeAg negative CHB patients treated by pegylated inter-Journal of Hepatology 20
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Open access under CC BY-NC-ND license.feron [8]. The heterogenous results obtained in different parts of
the world suggest that there may be some unrecognized factor(s),
which may have an impact on HBsAg levels, before, during and
after completion of anti-viral therapy.
In the present issue of the Journal, Brunetto and an experi-
enced group of investigators in the ﬁeld, report the results of
a new retrospective analysis of an old multi-center study on
the impact of HBV genotypes on the ﬁve year kinetics of HBsAg
levels in HBeAg negative CHB patients with genotypes A, B, C,
and D, treated with pegylated interferon a2a with or without
lamivudine [9]. Two cohorts of patients were evaluated: Cohort
1 included 117 patients with available serum samples collected
at baseline, week 12, 24, 48, 72 or end of treatment (EOT) as
well as at 5 years after completion. Cohort 2 included 199
patients with available serum samples at baseline, EOT and at
5 years. Long-term virologic response was deﬁned as a viral load
6104 copies/ml corresponding to 1.78  103 IU/ml at 5 years.
The major ﬁndings of this study suggest that: (1) Baseline
HBsAg levels and HBsAg kinetics vary signiﬁcantly between
genotypes tested. For example, baseline HBsAg concentrations
were highest in genotype A patients followed by genotype D
and lowest for genotypes B and C. In contrast, baseline viral load
and ALT levels were similar across genotypes. (2) Patients with
genotypes A, D, and B had a heterogenous response to interferon
therapy manifested by different slops of HBsAg decline in
responders and non-responders while the mean decline of
HBsAg concentration was more pronounced across genotypes
A, B, and D in responders with long-term viral response as com-
pared to non-responders. In contrast, the almost absent decline
in HBsAg levels along time in genotype C patients did not
enable distinction between responders and non-responders. (3)
The early on-treatment timeframe for recognition of responders
following treatment initiation was observed between week 12–
24 of treatment for genotype A and between baseline and week
12 for genotype B. Consequently, these observations may facili-
tate improved deﬁnition of treatment stopping rules as sug-
gested recently for interferon treated genotype D patients with
lack of HBsAg decline and <2 log10 decrease in viral load at
week 12 [10]. (4) HBsAg concentration cut-off levels for identi-
ﬁcation of treatment response as determined by ROC analysis
were highest for genotype D at 1000 IU/ml followed by
400 IU/ml for genotype A, 75 IU/ml for genotype C and 50 IU/
ml for genotype B. Genotype speciﬁc positive predictive13 vol. 59 j 1151–1152
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cut-off values (PPV) of HBsAg concentration at week 48 and for
5 years post treatment were relatively high for all genotypes
tested except for genotype B treated patients. Negative predic-
tive values (NPV) were high irrespective of genotype (see Table 2
[9]).
Comment: The interpretation of this important analysis is
indeed complex. Until recently, most reports on utilization of
HBsAg quantiﬁcation did not include a detailed analysis of pre,
intra and post treatment response across genotypes. The results
of the present study suggest that interpretation obtained
through ‘‘simple’’ HBsAg quantiﬁcation in such patients may
not be sufﬁcient and possibly misleading for deﬁnition of new
stopping rules for treatment. The newly described genotypic
cut-off values and variable kinetics of HBsAg may improve our
ability to predict the response to and stop (or prolong) of inter-
feron treatment. Yet, as the authors themselves state in their
balanced discussion, it seems pre-mature to utilize genotype
speciﬁc quantiﬁcation for treatment decisions in HBeAg nega-
tive CHB patients. Although original but also intriguing these
results require conﬁrmation by a much larger sample size with
balanced representation of genotypes before incorporating the
conclusions into clinical practice guidelines. The paper by Bru-
netto et al. [9] adds new and important information but is not
easy to read. It contains a wealth of additional data not dis-
cussed above. The limitations of the analysis are also described
in detail in the discussion. HBsAg quantiﬁcation in clinical prac-
tice is still a research tool, which requires more attention from
the scientiﬁc community. Thus, despite the availability of three
excellent commercial assays, the answer to a recent editorial
entitled ‘‘Is HBsAg quantiﬁcation ready for prime time?’’ (7)
is: NOT YET.Conﬂict of interest
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